CTOs on the Move

R2 Technology

www.r2tech.com

 
R2 Technology, Inc. is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.r2tech.com
  • 2585 Augustine Dr
    Santa Clara, CA USA 95054
  • Phone: 408.352.0100

Executives

Name Title Contact Details

Similar Companies

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.

Alphora Research Inc

Alphora Research Inc is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Yourgene Health

Yourgene Health, an integrated technologies and services business, enabling the delivery of genomic medicine. Our Expertise: Yourgene has >10 years of experience and expertise in liquid biopsy through NIPT, sample preparation and now precision medicine.

ADF Engineering Inc

ADF Engineering Inc is a Miamisburg, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CymaBay

CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline.